Follow The Filings

SRPT Sarepta Therapeutics

Sarepta Therapeutics earnings company data as of 7:31 PM ET 11/12

History

1 period, newest first. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 5 Nov EPS 0.36 — —
Rev $350.1M $381.4M Beat +8.9%

Insider trades

Open-market buys and sales by SRPT's executives, directors and 10% owners in the last 12 months, from their Form 4s

All SRPT insider trades
  • None no insider bought on the open market
  • $417K sold by 2 insiders outside a trading plan
  • None no planned (10b5-1) sales
  1. Stephen Mayo Director
    Sale
    $123K 7,239 shares at $17.02 80% of stake
    Traded Mar 12 Filed Mar 13
  2. Ian Michael Estepan COO
    Sale
    $294K 13,187 shares at $22.31 6.4% of stake
    Traded Dec 16, 2025 Filed Dec 18, 2025

Also filed in the last 12 months, not counted as buying or selling: 27 share withholdings for taxes, 14 stock grants, and 6 option exercises.

SEC filings

Recent issuer filings from EDGAR, 20 shown.

Filed Form Detail Links
SCHEDULE 13G/A —
SCHEDULE 13G —
10-Q
8-K 2.02,9.01
8-K 1.01
SCHEDULE 13G/A —
SCHEDULE 13G —
10-Q
8-K 2.02,9.01
SCHEDULE 13G/A —
SCHEDULE 13G/A —
8-K 5.02,7.01,9.01
8-K 5.02,5.07,9.01
10-Q
8-K 2.02,9.01
SCHEDULE 13G —
SCHEDULE 13G —
DEF 14A
DEFA14A
SCHEDULE 13G/A —

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

More on the shelf